Palisade Bio - PALI Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 17.92 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.24
▲ +0.39 (10.13%)

This chart shows the closing price for PALI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Palisade Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PALI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PALI

Analyst Price Target is $5.00
▲ +17.92% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Palisade Bio in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 17.92% upside from the last price of $4.24.

This chart shows the closing price for PALI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Palisade Bio. This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/19/2022Maxim GroupDowngradeBuy ➝ HoldLow
2/2/2022LADENBURG THALM/SH SHInitiated CoverageBuy$5.00High
8/31/2021Maxim GroupInitiated CoverageBuy$7.00High
(Data available from 12/5/2017 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/8/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/7/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/6/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/5/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/5/2022

Current Sentiment

  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

Palisade Bio logo
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Read More

Today's Range

Now: $4.24
Low: $3.77
High: $4.70

50 Day Range

MA: $0.97
Low: $0.07
High: $4.24

52 Week Range

Now: $4.24
Low: $2.04
High: $106.73

Volume

1,268,800 shs

Average Volume

393,672 shs

Market Capitalization

$1.86 million

P/E Ratio

0.30

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Palisade Bio?

The following Wall Street analysts have issued reports on Palisade Bio in the last year: LADENBURG THALM/SH SH, and Maxim Group.
View the latest analyst ratings for PALI.

What is the current price target for Palisade Bio?

1 Wall Street analysts have set twelve-month price targets for Palisade Bio in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 17.9%. LADENBURG THALM/SH SH has the highest price target set, predicting PALI will reach $5.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $5.00 for Palisade Bio in the next year.
View the latest price targets for PALI.

What is the current consensus analyst rating for Palisade Bio?

Palisade Bio currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PALI will outperform the market and that investors should add to their positions of Palisade Bio.
View the latest ratings for PALI.

What other companies compete with Palisade Bio?

How do I contact Palisade Bio's investor relations team?

Palisade Bio's physical mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company's listed phone number is (858) 704-4900 and its investor relations email address is [email protected] The official website for Palisade Bio is www.palisadebio.com. Learn More about contacing Palisade Bio investor relations.